Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.
The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...
Changes to vaccine recommendations under Health Secretary Robert F. Kennedy Jr. are confusing professionals in the pharmaceutical and insurance industries.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback